AU594650B2 - Stable DNA constructs for expression of alpha-1-antitrypsin - Google Patents

Description

I-

4 C O M M O N W E A L T PO? A S T R A L I A PATENT ACT 1952 COMPLETE SPECIFICATION (Original) FOR OFFICE USE 594650 Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority: This domunylt c on 49 and is con-ct I printing, Related Art: 49112-'s o *0 00 0 000 0 ~0 0 o 00 00 0800 00 0 0 00 0 0 0 a *00 0 0000 Names. of Applicants: ZYMOGENETICS, INC.

GLENN KAWASAKI

AND

Addresses of Applicants: 2121 North 35th Street, Seattle, Washington 98103, United States of America.

1547 16th Avenue, East, and Seattle, Washington 98112, United States of America.

Actual Inventor(s): respectively Glenn KAWASAKI Leslie BELL

C

7 CC

C

Address7for Service: DAVIES COLLISON, Patent Attorneys, 1 Little Collins Street, Melbourne, 3000.

Complete Specification for the invention entitled: STABLE DNA CONSTRUCTS FOR EXPRESSION OF ALPHA-1-ANTITRYPSIN The following statement is a full description of this invention, including the best method of performing it known to us

-I-

H

"I"

r* I -la- STABLE DNA CONSTRUCTS FOR EXPRESSION OF ALPHA-1-ANTITRYPSIN o oo oo o 00o o o 0 01 L Background of the Invention The use of microorganisms for the production of useful polypeptide products through recombinant DNA technology is becoming established as an industry. Foreign genetic material may be introduced into a culture of microorganisms, and, given the proper intracellular and extracellular conditions, the desired protein product(s) may be synthe- 10 sized from the foreign gene(s). Such genetic material is commonly introduced into microorganisms in the form of plasmids, which are autonomously replicating extrachromosomal elements. In order to ensure the maintenance of plasmids within a culture of transformed cells, it has been necessary to grow those cells under special conditions. In the absence of such conditions, the plasmids, which may be inherently unstable, will not be maintained, and the cell population will revert to the untransformed state.

Increased plasmid stability and copy number are important to the biotechnology industry as a means of maintaining the production of plasmid-encoded proteins at a consistently high level. Previously reported attempts to increase p.-asmid stability do not appear to be optimal for commercial application. The introduction of yeast centromeres into ARS-bearing plasmids, while enhancing stability, has been shown to markedly decrease plasmid copy number (Clarke and Carbon, Nature 287: 504-509, 1980 and Stinchcomb, et al., J. Molec. Biol. 158; 157-179, 1982). Linear centromeric yeast plasmids similarly show an inverse relationship r-

I

i 'i yii i -2between stability and copy number (Murray and Szostak, Nature 305: 189-193, 1983).

Plasmids typically contain gene sequences, known as selectable markers, which encode antibiotic resistance or complement nutritional requirements of the host cell. To select for the presence of such plasmids, transformed cells must thus be grown in special media which contain a selective drug or which are depleted for specific nutrients. These media requirements may be both expensive and prohibitive of optimal cell growth rates during the large-scale fermenta- Stion process. Many such plasmids have been reported in the literature. Those comprising antibiotic drug resistance genes include pBR322 (Bolivar, et al., Gene 2: 95-113, 1977) and its derivatives, such as the pUC vectors (Vieira 15 and Messing, Gene 19: 259-268, 1982) which carry a gene for ampicillin resistance; and pBR325 (Prentki, et al., Gene *o 14: 289, 1981) which carries resistance genes for ampicil- S-lin, tetracycline, and chloramphenicol. Plasmids which complement host nutrient requirements include the yeast vectors YEpl3 (Broach, et al., Gene 8: 121-133, 1979), which carries the LEU2 gene; and YRp7' (Stinchcomb, et al., Nature 282: 39, 1979), which carries the TRP1 gene.

S Alpha-1-antitrypsin is a protease inhibitor, the principal function of which is to inhibit elastase, a broad spectrum protease. Lung tissue in mammals is particularly vulnerable to attack by elastase, therefore alpha-1-antitrypsin deficiency or inactivation may lead to loss of lung tissue elasticity and subsequently to emphysema. Loss or reduction of alpha-1-antitrypsin activity may be a result of oxidation of alpha-l-antitrypsin due to environmental pollutants, including tobacco smoke. Deficiency of alpha- 1-antitrypsin may result from one of several genetic disorders. See Gadek, James and R. D. Crystal, "Alpha- 1-Antitrypsin Deficiency", The Metabolic Basis of Inherited Disease, Stanbury, J. et al., Ed. McGraw-Hill, New York 7 -3- (1982) pp. 1450-1467; and Carroll, et al., Nature 2988, 329-334 (1982) It is therefore an object of the present invention to provide DNA constructs containing a DNA sequence encoding alpha-1-antitrypsin and, as selectable markers, gene sequences whose products are essential for the viability or normal growth of the host cell on complex media.

It is another object of the present invention to provide transformant strains of microorganisms containing plasmids 1i which are selectable by growth on complex media and which are capable of expressing alpha-1-antitrypsin.

It is a further object of the present invention to provide 6 S strains of microorganisms that are deficient in essential functions which may act as hosts for DNA constructs 4: 15 carrying gene sequences which complement these defective essential functions and are capable of expressing alpha-antitrypsin.

'.9o It is yet another object of the present invention to provide methods for producing alpha-l-antitrypsin in transformed microorganisms, wherein the alpha-l-antitrypsin is a Sproduct of a gene carried on a DNA construct which con- Stains, as a selectable marker, a gene sequence which complements a deficiency in an essential gene in the host microorganism.

Other objects of the invention will become apparent to those skilled in the art.

Summary of the Invention According to the present invention, there are provided DNA constructs and appropriate host cells such that the constructs are capable of expressing alpha-1-antitrypsin and are maintained at high copy number without the need for special selective media. Growth in such conditions may -4result in faster growth, greater cell density, and reduced production costs.

The present invention further provides a method for producing alpha-l-antitrypsin in a host cell having a deficiency in a function necessary for normal cell growth in complex media, comprising the step of transforming the host cell with a DNA molecule comprising a gene which complements the deficiency and a sequence coding for alpha-l-antitrypsin.

As used herein the term "DNA construct" means any DNA molecule which has been modified by man in a manner such that the nucleotide sequences in the molecule are not identical to a sequence which is produced naturally. The term "DNA construct" also includes clones of DNA molecules which have been so modified. The term "expression vector" is defined as a DNA construct which includes an autonomous o site of replication, a site of transcription initiation and o o at least one structural gene coding for a protein which is o to be expressed in the host organism. The expression vector will usually also contain appropriate control regions such as a promoter and terminator which control the expression of the protein in the host organism. Expression vectors according to the present invention will also contain a selection marker comprising an essential gene as described herein.

The term "plasmid" will have its commonly accepted meaning, Si.e., autonomously replicating, usually close-looped, DNA.

In the accompanying drawings: Figure 1 illustrates the construction of plasmid pB4.

Figure 2 illustrates the construction of plasmid Figure 3 illustrates the construction of plasmid -l r. 0 0I 00 00 *000 *o 0 00 0 *n 0 0 0004 *040 Figure 4 shows a Southern blot of DNA from S. cerevisiae strain A2.7.c co-transformed with plasmids pB5 and The blot was probed with a 2.5 kb BamHI-HindIII fragment from the 5' flanking region of CDC4 in order to test for disruption of the genomic CDC4 locus. Lane a contains DNA from cells transformed with pB5 alone; Lane b, untransformed cells; Lanes c-h, co-transformants. Arrows indicate the genomic fragments hybridizing to the probe.

Figure 5 shows the sequences of the S. pombe POT1 and S.

cerevisiae TPI1 genes together with the respective inferred protein sequences. The entire S. pombe TPI protein sequence is given. The sequence of the S. cerevisiae protein is given only where it differs from the S. pombe sequence. The methionine at position 1 in the S. cerevisiae protein sequence is not present in the mature protein.

Figure 6 illustrates the construction of the plasmid pCPOT.

Figure 7 illustrates the construction of the plasmid pFATPOT.

Figure 8 illustrates the construction of the plasmid pTPI-LEU2.

Detailed Description The present invention is based in part upon the discovery that essential genes may be used as selectable markers on DNA constructs such as plasmids which are capable of expressing alpha-l-antitrypsin. An "essential gene" is defined as any gene that codes for a function necessary for cell viability or normal growth on complex media. Complex media are those media in which the nutrients are derived from products whose composition is not well defined, such crude cell extracts, meat extracts, fruit juice, serum, protein hydrolysates, etc. Hence, to select for a desired transformant according to the present invention, the selection growth medium will be merely a conventional cc c I: i

I

.E

i i L131111111~ -h 3-(1 IICI III~I~ 11I YI I-Il-- a 0i Oa S0 a a a o 09a 0000Q a a a Ia *000 9 a(( -6complex growth medium, not a special medium containing a relatively expensive antibiotic, metal antagonist, or other agent lethal to the untransformed host cell, or lacking one or more specific nutrients required by the untransformed host. Essential genes include, but are not limited to, genes required for cell division, membrane biosynthesis, cell wall biosynthesis, crganelle biosynthesis, protein synthesis, carbon source utilization, RNA transcription, and DNA replication.

In order to use an essential gene as a selectable marker on a DNA construct, such as a plasmid, it is necessary to provide an appropriate mutant host cell strain. Using the one-step gene disruption method of Rothstein (Meth. in Enzymology 101: 202-210, 1983) or the co-transformation 15 procedure described herein, suitable host strains may be constructed which carry deletions in an appropriate essential gene in the genome. Such deletion mutants grow when the mutation is complemented by a function coded by plasmid-borne genetic material. It is preferred that the deletions in the essential gene or genes of the genome of the host comprise substantial segments of the coding region and/or flanking regions. I the mutation or mutations in the essential gene are accomplished in a manner to achieve only point mutations, then there is a likelihood that the mutant host cell will revert to wild-type by mutation or a recombination repair mechanism, thereby reducing or eliminating the selectivity achievable by use of the plasmid-borne gene.

Essential genes often exist in multiple copies (such as histone or ribosomal RNA genes) and/or in multiple, related forms called gene families (such as different hexokinase genes, or different DNA polymerase genes). In such cases, these redundant functions may be sequentially mutated to make a host cell which is multiply deficient for a given essential function. However, by using a high copy number plasmid to increase the activity of the gene, a single Y j x. ii pAi ft lA 04*0 ao *0 *4 ft 0 *4 ft4* -7essential gene on a plasmid may complement multiple host cell deficiencies. A high copy number plasmid is desirable because an increase in copy number of a cloned foreign gene may result in an increase in the production of the protein product encoded by said gene.

The selection for transformants containing high copy numbers of plasmids with essential genes may be accomplished by reducing the expression levels of each plasmid-borne essential gene and/or by reducing the activities of the gene products encoded by the plasmid-borne selectable marker. One approach is to mutate the essential genes such that the transcription and/or translation rates of the genes are reduced or the gene products are altered to have lower specific activities. Another method for decreasing the expression levels of essential genes used as selectable markers is to use a gene from another organism to complement defects in the host cell. Such foreign genes may be naturally defective for expression in a host cell because the signals for transcription and/or translation may be suboptimal in a different species or the gene product may have decreased activity or stability because it is in a foreign cellular milieu.

A broad range of functions necessary for cell viability or normal growth on complex media exists. A defect or dele- 25 tion in an essential gene may result in lethality, a decrease in the rate of cell division, cessation of cell division, termination of DNA, RNA, or protein synthesis, termination of membrane synthesis, termination of cell wall synthesis, termination of organelle synthesis, defects in sugar metabolism, etc. Examples of essential genes include the CDC (cell division cycle) genes of the yeast Saccharomyces cerevisiae (for review see Pringle and Hartwell, "The Saccharomyces cerevisiae Cell Cycle", in Strathern, et al., eds., The Molecular Biology of the Yeast Saccharomyces Life Cycle and Inheritance, 97-142, Cold Spring Harbor, 1981), the genes coding for functions of the S. cerevisiae 4 I *sr i 12 -8and E. coli glycolytic pathways, and the SEC (Novick and Schekman, Proc. Nat. Acad. Sci. USA 76: 1856-1862, 1979 and Novick, et al., Cell 21: 205-215, 1980) and INO (Culbertson and Henry, Genetics 80: 23-40, 1975) genes of S. cerevisiae.

One preferred class of essential gene-deficient host cells contains defects in CDC genes known as cdc mutations, which lead to stage-specific arrests of the cell division cycle.

Most cdc mutations produce complete blockage of events essential to the cell cycle by affecting either the synthesis or function of the particular CDC gene products. Such mutations may be identified by their effects on events which can be monitored biochemically or morphologically.

Most known cdc mutations are conditionally lethal temperature sensitive) mutations, which result in the O °cessation of normal development of mutant cells grown under oo restrictive conditions. However, the primary defect o o resulting from a cdc mutation need not be a defect in a ooo stage-specific function per se. For example, continu- S o 20 ously-synthesized gene products may have stage specific functions; a defect in the yeast glycolytic gene PYK1 (for the enzyme pyruvate kinase) is allelic to the cell division cycle mutation cdcl9 (Kawasaki, Ph.D. Thesis, University of Washington, 1979). This mutation results in cell cycle arrest at the G1 phase of cells incubated in the typical yeast complex medium YEPD yeast extract, 2% bactopeptone, and 2% dextrose). Thus, whether the cdc mutation results in a defect in a stage-specific function, or whether it causes an inhibition or disabling mutation of a gene product having a stage-specific function, the effect of the defect may be monitored.

Pringle and Hartwell (ibid.) describe the function of some 51 CDC genes. For use in carrying out the present invention, such genes may be isolated from gene libraries by complementation in a strain carrying the desired mutation. Gene libraries may be constructed by commonly i j

I~

i jL lllllllll~lli-- I 111 ~I ~llll~- pl 1~ II U

I

4 II 4I 44 44 4 4 -9known procedures (for example, Nasmyth and Reed, Proc.

Natl. Acad. Sci. USA 77: 2119-2123, 1980; and Nasmyth and Tatchell, Cell 19: 753-764, 1980). Strains carrying the desired cdc mutation may be prepared as described herein, or may be obtained from depositories accessible to the public, such as, the American Type Culture Collection and the Berkeley Yeast Stock Center.

A second preferred class of essential genes are those encoding products involved in the glycolytic pathway, including genes coding for metabolic enzymes and for regulatory functions. Examples of glycolytic pathway genes in S. cerevisiae which have been identified are the glycolysis regulation gene GCR1 and the genes coding for the enzymes triose phosphate isomerase, hexokinase 1, hexokinase 2, phosphoglucose isomerase, phosphoglycerate kinase, phosphofructokinase, enolase, fructose 1, 6-bisphosphate dehydrogenase, and glyceraldehyde 3-phosphate dehydrogenase. As noted above, the pyruvate kinase gene has been identified and described by Kawasaki. A plasmid 20 containing a yeast phosphoglycerate kinase gene and accompanying regulatory signals has been described by Hitzeman, et al. Biol. Chem. 225: 12073-12080, 1980).

Isolation and sequencing of the yeast triose phosphate isomerase gene TPI1 has been described by Alber and Kawasaki Mol. Appl. Genet. 1: 419-434, 1982) and by Kawasaki and Fraenkel (Biochem. Biophys. Res. Comm. 108: 1107-1112, 1982).

A particularly preferred glycolytic gene is TPI1, which codes for the yeast triose phosphate isomerase, an enzyme which catalyzes the interconversion of glyceraldehyde-3phosphate and dihydroxyacetone-3-phosphate and is therefore essential for glycolysis and gluconeogenesis. In S.

cerevisiae the single genetic locus, TPII, codes for this function. Cells carrying mutations in TPI1 do not grow on glucose and grow poorly on other carbon sources.

j

I-

i i j r I l **it^ a;xu 00 o a c2 Ci 0 cc00 ci,, 0cicic cc-r '4

.A

The S. cerevisiae TPI1 gene was isolated by complementation of the tpil mutation (Alber and Kawasaki, ibid., and Kawasaki and Fraenkel, ibid.). The triose phosphate isomerase gene from the fission yeast Schizosaccharomyces pombe (POT1) has been isolated by complementation of the same S. cerevisiae mutation, and has been sequenced as shown in FIG. 5. Sequencing of the S. pombe gene, designated POT1, has demonstrated that the S. pombe TPI protein is homologous to the TPI protein of S. cerevisiae.

While in the usual case the essential gene which is utilized in the DNA construct (plasmid) will be a wild-type gene from the host species, in some cases it will be preferable to use an essential gene which is foreign to the host cell because the foreign gene may be naturally defective, and thereby selectable to high plasmid copy number. As an example of such a foreign essential gene being used, one of the examples herein shows that the S.

pombe POT1 gene may be effectively used as a selectable marker in an S. cerevisiae host.

The DNA constructs according to the present invention containing essential genes as selectable markers will be transformed into mutant host cells which are defective in the function of the essential gene. Properly mutated host cells must either be prepared or, may be readily available from a public depository. Mutation of the wild-type cell to obtain a proper mutant may be accomplished according to conventional procedures. For example, wild-type cells may be treated with conventional mutagenizing agents such as ethane methyl sulfonate and transformed with a plasmid containing an essential gene to identify the colonies where complementation occurs. Alternatively, the genome may be disrupted to create a specific mutation (Rothstein, ibid).

The stability of the plasmid containing the essential gene in the host cell may be dependent on the absence of homologous essential gene sequences in the host cell. The r

J

i i a 1 1 I WI

B

a a a at a aao e a a at a iir -11genetic defects in the host ensure that the plasmid will be maintained since growth of the host cell will not occur or will be severely limited by the lack of the essential gene function. Additionally, the integrity of the plasmid itself may be dependent upon the absence of homology between the plasmid-borne essential gene and the corresponding locus in the host genome, because recombination between respective plasmid and genomic loci may cure the cell of both the mutation and the plasmid. Thus, it is preferred that mutation in the host cell genome which inactivates the genomic essential gene be of a substantial nature, deletions be made from the DNA sequences of the coding section and/or flanking regions of the chromosomal gene. Once this is accomplished, curing of the genomic mutation by recombination is less likely to occur.

The plasmids of the present invention are unexpectedly stable when maintained in the appropriate mutant host cells. A preferred host cell is yeast; however, other eukaryotic cells may be utilized, as well as prokaryotic 20 cells. In the case of yeast cells, the stability of the plasmids according to the present invention appears to exceed even that of yeast plasmids containing centromeres.

Circular centromere plasmids are among the most stable plasmids previously reported for yeast, but suffer from an extremely low copy number (Clarke and Carbon, ibid. and Stinchcomb, et al., 1982, ibid.). Linear centromeric yeast plasmids are either unstable or present at low copy number, depending on plasmid length (Murray and Szostak, ibid.).

It is therefore an unexpected advantage that improved stability of plasmids bearing an essential gene is achieved.

The POT1 and CDC4 genes are two examples of the utility of essential genes as selectable markers on expression vectors. These two genes belong to a broad class of genes that are required for cell proliferation on complex media.

The use of other essential genes may allow for plasmid t i -12selection in plant or animal tissue culture which involves complex growth conditions and at the extreme may allow for the maintenance of plasmids in cells receiving nutrition from blood, serum, or sap of living animals or plants.

Data obtained from experiments using plasmids described herein show that human alpha-l-antitrypsin (AT) production is doubled by the use of the S. pombe POT1 gene as the selectable marker, when compared to AT production obtained with similar plasmids bearing a traditional auxotrophic selectable marker, LEU2. These results indicate that POT1 Scontaining plasmids are functionally greater in copy number than the non-POTI plasmids from which they are derived.

The techniques used to produce the DNA constructs, in particular the plasmids, according to the present inven- 4 0o C 15 tion, involve conventional methods. The essential gene to be utilized in the DNA construct may be isolated rom a library by using a labeled DNA probe if the structure of the gene is known, or identified by ligating segments of the DNA library to conventional vectors, transforming the vectors into a mutant cell deficient in the particular essential gene and searching for colonies which are complemented. Once an appropriate DNA fragment containing the essential gene is identified it will be ligated to a vector which contains a DNA sequence coding for the structural protein which will be expressed. The essential gene may be iutilized together with its own promoter and other controls necessary for expression within the host organism. Alternatively, a heterologous promoter may be utilized to *t r increase or decrease expression of the essential gene.

Methods of ligation of DNA fragments are amply described and are well within the skill of those of ordinary skill in the art to perform.

After preparation of the DNA construct it will be transformed into the host organism under transforming conditions. Techniques for transforming prokaryotes and -13eukaryotes (including tissue culture cells) are known in the literature.

As described above the host organism must be deficient in the essential function for selection of the essential gene on a plasmid. Mutant host strains are available from conventional depositories or may be made by conventional means from wild-types by mutagenesis and screening for the mutant carrying the proper mutation.

The transformed host may then be selected by growth on 1Q conventional complex medium. In the case of yeast, a conventional medium such as YEPD yeast extract, 2% bactopeptone, and 2% dextrose) may be used. The selectable markers comprising essential genes according to the present SB", invention may be used as markers wherever appropriate in a 15 any DNA construction and thus it will be recognized that ,4 constructs containing the essential gene selection markers S" according to the present invention have many uses. The °0 following examples are offered by way of illustration of such use, not by way of limitation.

Unless otherwise indicated, standard molecular biology methods were used. Enzymes were obtained from Bethesda Research Laboratories, New England BioLabs, and Boehringer Mannheim Biochemicals, and were used as directed by the manufacturer or as described by Maniatis, et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor SLaboratory, 1982) E. coli cultures were transformed by the calcium chloride method, also disclosed in Maniatis, et al. (ibid.). Yeast cultures were transformed by the method tof Beggs (Nature 275: 104-108, 1978), with modifications as i described herein.

i I 1 ii o )O 0 0 0 .a o <s r o o o a o or, 0000 o) a 9) 0 00 00 0 0 t& 00 0J -14- Example 1 The S. cerevisiae CDC4 gene as selectable marker A. Construction of a stable CDC4-containing plasmid A yeast genomic library was constructed by partial digestion of yeast DNA with Sau3A, size selection on sucrose gradients, and insertion of the selected fragments into the yeast vector YRp7 which had been digested with BamHI (Nasmyth and Reed, Proc. Natl. Acad. Sci. USA. 77: 2119- 2123, 1980). A recombinant plasmid containing the CDC4 gene was isolated by transformation of yeast strains (MATa cdc4-4 leu2 trpl lysl ural) and GEB7 (MATa cdc4-3 leu2 trpl lysl) with the library. These strains were derived from strains A364A cdc4-3 and A364A cdc4-4 (Hartwell, et al., Genetics 74: 267-286, 1973) by crossing with a strain known to transform at high frequency (K79 [MATa leu2 trpl] (Nasmyth, et al., Nature 289: 244-250, 1981; Tatchell, et al., Cell 27:25-35, 1981) followed by backcrossing to high transforming strains (K79 and K80 [MATa 20 leu2 trpl lysl]) to obtain the cdc4-3 and cdc4-4 mutations in the desired genetic background (leu2 trpl). Selection of transformants for tryptophan prototrophy and the ability to grow at the restrictive temperature (370) identified one such plasmid (designated pJY35) which was shown to integrate into the genome and map to the CDC4 locus. Spontaneous plasmid integrants were identified on the basis of their selective growth advantage. This growth advantage is due to the presence, on the original plasmid, of a CDC4linked gene which is deleterious to cell growth when 30 present at high copy number when the plasmid is not integrated into the host genome) In the integrants, the TRP1 plasmid marker was shown to be genetically linked to SUP11, which is linked to CDC4 on chromosome VI (Mortimer and Schild, "Genetic Map of Saccharomyces cerevisiae" in Strathern, et al., eds., The Molecular Biology of the Yeast Saccharomyces cerevisiae Life Cycle and Inheritance, 641-651, Cold Spring Harbor, 1981). The cdc4-3 1 1

I

i t :i

I

II:

(a f 00 00 0 0 01 0 (0 4 'k1 p..

r xii :li i-, 0 00 00 0 ao o o0 0 0 00 a 00 00 t complementing region was purified from pJY35 as a 6.4kb BamHI fragment and was joined, using T4 DNA ligase, to the vector YRp7 (Struhl, et al., Proc. Natl. Acad. Sci. USA 76: 1035-1039, 1979) which had been cleaved with BamHI. This construct is known as pJY51, and is illustrated in FIG. 1.

Referring to FIG. 1 the CDC4 coding region was purified away from flanking genomic DNA sequences in the following manner. Plasmid pJY51 was cleaved with HindIII and the 3.6kb fragment comprising the CDC4 region was subcloned in the bacterial plasmid pBR322. This construct was digested to completion with BamHI, partially digested with HincII, and the ca. 2.3 kb CDC4-containing fragment was purified.

The HincII fragment end was converted to a BamHI end by the addition of linker sequences (sequence:5'CCGGATCCGG3') (obtained from Collaborative Research) and subsequent digestion with BamHI to remove excess linkers. The resulting fragment, comprising approximately 1.9 kb of the CDC4 gene, was inserted into the BamHI site of YRp7 to produce plasmid pJY70. This plasmid was shown to complement the cdc4-3 mutation as described above. Although the 1.9 kb fragment lacks small portions of both the and 3'-coding regions of the CDC4 gene, it surprisingly complements the temperature-sensitive defect. Presumably, transcription and translation of the CDC4 sequence is controlled by se- 25 quences located in the pBR322 regions of the plasmid, allowing for production of a functional gene product.

Plasmid pJY70 was cleaved with EcoRI to remove the yeast TRP1 and ARS1 sequences and was re-ligated, yielding a hybrid plasmid comprising pBR322 and CDC4 sequences. This plasmid is known as pJY71, and is illustrated in Figure 1.

The 1.9 kb yeast sequence was purified from pJY71 as a BamHI-HindIII fragment. This fragment was joined to pBR322 which had been linearized by digestion with BamHI and HindIII, to produce the plasmid pB4, and is illustrated in Figure 1.

Vt 0 b j -16- The CDC4 region was re-isolated from pB4 for insertion into a high copy number yeast vector. Such a vector will contain an origin of replication of the yeast 2 p plasmid, and one or more restriction enzyme cleavage sites which will serve as cloning sites for foreign genes of interest.

Preferably such sites will be unique sites on the plasmid.

A preferred vector is MW5, which comprises the yeast 2p plasmid replication origin and unique EcoRI and BamHI cloning sites. Referring to FIG. 2 plasmid MW5 was derived from plasmid YRp7' (Stinchcomb, et al., Nature 282: 39-43, 1979) by partial digestion with EcoRI to cleave, on average, one of the two EcoRI sites per molecule. The resulting unpaired ends of the linear molecules were filled in using DNA polymerase I (Klenow fragment) and the resulting blunt ends were re-joined using T4 DNA ligase. The resulting plasmid which retained the EcoRI site adjacent to the ARS1 sequence was then selected. The ARS1 sequence was o o« removed by digestion with PstI and EcoRI, and replaced with Sthe PstI-EcoRI fragment of plasmid YEpl3 (Broach, et al., 20 Gene 8: 121-133, 1979) which comprises the replication origin of yeast 2p DNA. The resulting plasmid, designated o 0 MW5, is illustrated in FIG. 2.

1it To construct the final CDC4-containing stable plasmid, was cleaved with EcoRI and BamHI. The CDC4 fragment was purified from plasmid pB4 by digesting the plasmid with BamHI and EcoRI. The two fragments were joined, using T4 DNA ligase, and the chimeric molecules so produced were S1transformed into E. coli strain RRI (Nasmyth and Reed, ibid.) with selection for ampicillin-resistant, tetracycline-sensitive colonies. Plasmid pB5 (shown in FIG. 2), isolated from one such colony, comprises the yeast 2p replication origin, pBR322 plasmid sequences, the select- S. able marker TRP1, 1.9 kb of the yeast CDC4 coding sequence, and a unique EcoRI cloning site.

i ~4- 7 -i -17- B. Construction of a plasmid for disruption of host CDC4 gene The stability, in a transformed host, of the CDC4-containing plasmid according to the present invention is dependent on the lack of a functional CDC4 gene in the host. It is further desirable that no homology exists between the host genome and the CDC4-containing stable plasmid in order to prevent recombination between plasmid and chromosomal DNA's. To obtain a yeast strain having a suitably deleted CDC4 locus, a yeast host containing the wild-type CDC4 gene may be transformed with a linearized plasmid fragment having a "disrupted" CDC4 gene (Rothstein, ibid.). The linearized plasmid fragment is a preferred transforming agent because the free ends of the fragment may enhance recombination within the CDC4 region. Such a plasmid fragment will have intact CDC4 flanking regions at its ends o o to facilitate recombination with the intact genomic CDC4 o locus. The genetic material inserted between the CDC4 f flanking regions of the plasmid fragment will code for a S 20 phenotypic characteristic which can be selected in the S' transformed host (a selectable marker such as TRP1 or LEU2). The disrupting plasmid will preferably also lack a yeast origin of replication in order to select for the integration of the disrupted CDC4-selectable marker sequence into the host genome. Following transformation with the linearized plasmid, genetic recombination results in the substitution of the disrupted sequence for the genomic sequence of the host. Cells in which the CDC4 gene has now been deleted are then selectable according to the marker used in the disruption.

k A method for a one-step disruption of a host genome is S; described by Rothstein (ibid.). As described above, disruption is performed with the added improvement of co-transforming a host strain with an intact stable plasmid and a linearized plasmid such that in addition to achieving .4 00 4 0 0 0 O 0 *044 0 4 4 0* 4 0I U.

44 4 0( 4 4.I -18disruption of the host genome, transformation of the host with the stable plasmid is also effected.

A preferred plasmid for disruption of the host CDC4 locus is pB15L, shown in Figure 3. It comprises the yeast LEU2 gene inserted between the flanking regions of CDC4, and the vector pUC13 (Vieira and Messing, Gene 19: 259-268, 1982 and Messing, Meth. in Enzymology 101: 20-77, 1983). When linearized at the junctions of yeast and vector sequences and transformed into a suitable yeast host strain, the plasmid produces a deletion of CDC4 in the host genome resulting from the substitution of the LEU2 sequence for the CDC4 region. In a host strain auxotrophic for leucine, disrupted transformants may then be selected on the basis of leucine prototrophy.

To construct plasmid pB15L, a 6.4 kb fragment comprising the CDC4 gene and its and 3'-flanking regions was purified from a BamHI digest of pJY51. This fragment was inserted into BamHI-digested pUC13 to produce the plasmid pBl4. Most of the CDC4 coding region was removed by 20 digesting pB14 with Clal and purifying the larger fragment which comprises the pUC13 and CDC4 flanking sequences. The fragment ends were modified by the addition of XhoI (BglII) "smart" linkers (Worthington Diagnostic), and the 2.8 kb BglII LEU2 fragment of YEpl3 (Broach, et al., Gene 8:121- 133, 1979) was joined to the resultant cohesive termini.

DNA so prepared was used to transform E. coli strain RRI.

Transformants were selected on the basis of leucine prototrophy, since the yeast LEU2 sequence complements the leuB defect in the E. coli host. Plasmid pB15L was purified from one such transformed colony.

Plasmid pB15L comprises only about 50 base pairs of the end of the CDC4 coding sequence in addition to the 5' and 3' flanking sequences. A comparision of the maps of plasmids pB5 and pB15L shows a lack of homology between their respective CDC4 sequences as the junction points of 4 ~Ij 44 4r -19the CDC4-LEU2 gene Lusion of pB15L are located outside the region of the CDC4 fragment present in pB5. Thiis lack of homology prevents recombination between pB5 and the disrupted CDC4 locus in the host cell.

C. Co-transformation of S. cerevisiae To simultaneously delete the genomic CDC4 gene and introduce plasmid pB5, yeast cells were co-transformed with BamHI-cleaved pB15L and intact plasmid pB5. The host strain to be used in the transformation should be auxotrophic for tryptophan and leucine in order to select simultaneously for plasmid pB5 and the genomic CDC4 disruption.

Strain A2.7.c (MATa cdc4-3 trpl leu2-2,112 lysl his3-11,15 canl obtained from a cross of strain A2 (MATa leu2-2,112 his3-11,15 cani; see Szostak, Meth. in Enzymology 101: 245-252, 1983) with strain GEB7 (see Example 1A) was used.

o 0o In a typical co-transformation experiment, 10ml of a culture of S. cerevisiae A2.7.c in log phase growth were t 'transformed with approximately 6p.g of BamHI-digested a lpg pB5, and 10lg calf thymus DNA as carrier. Transforma- 20 tion conditions were as described by Beggs (ibid.). Cells were plated on a medium lacking leucine and tryptophan.

They were grown overnight at 220 and shifted to 370.

Approximately 30 colonies were obtained. The control J transformation with pB5 alone and selection for tryptophan prototrophy produced approximately 1,000 transformants.

Six co-transformed colonies were analyzed to verify the disruption of the CDC4 locus and to test the stability of the pB5 plasmid. Genomic DNA was isolated from co-transformants by the method of Abraham, et al. (Cold Spring 30 Harbor Symposium Quant. Biol. 47: 989-998, 1983) and was digested with EcoRI and BamHI, electrophoresed on an agarose gel, and transferred to nitrocellulose (Southern, J. Mol. Fiol. 98: 503-517, 1975). The blot was probed with the 2.5 kb BamHI-HindIII fragment from the 5' flanking

II

1 region of CDC4 present in pB15L but absent from Figure 4 shows that the probe hybridized to a 6.4 kb fragment of DNA from untransformed cells (lane there is no EcoRI site within this 6.4 kb BamHI fragment. As the LEU2 sequence contains an EcoRI site, disruption of the CDC4 locus will result in a reduction in size of the hybridizing band (indicated by arrows in Figure This is the case for the transformants represented in lanes c, d, f, g, and h. Lane e shows a somewhat different pattern and retains the genomic-size band, indicating that deletion of the genomic CDC4 did not occur. (The smaller bands seen in lanes c through h are due to contamination of the gel-purified probe, as shown by the patterns of the controls in lanes a and b.) The six co-transformants were tested for plasmid stability by growing on complex medium (YEPD). Cells were grown for 30 generations in liquid YEPD at 250, then plated on YEPD at 250, and replica plated onto YEPD at 370, tryptophanless medium, and leucineless medium. Results summarized in S 20 Table 1 indicate that all co-transformants except #3 were 100% stable for the plasmid markers on complex media.

(Isolate number 3 is the same co-transformant represented in lane e of Figure 4).

SFurther stability tests were performed on two co-transformants, numbers 1 and 2. Testing was performed on 663 and 681 colonies respectively. After growth for 30 generations on EPD at 30°, all colonies were prototrophic for Stryptophan and leucine.

Co-transformant #1 was tested for growth rate at 220 and...

30 was found to grow at the same rate as an untransformed A2.7.c control.

Co-transformant #1 has been designated BELL1. It has been deposited with ATCC under accession number 20698.

'Y'

i I ~mra~- I -21- Example 2 Schizosaccharomyces pombe POT1 gene A. S. pombe POT1 gene as a selectable marker oo a o o 0 o *oD 00i *L I 0l

I

The Saccharomyces cerevisiae TPI1 gene codes for the triose phosphate iscmerase protein and has been obtained by complementing the tpil deficiency (Kawasaki and Fraenkel, ibid.; Alber and Kawasaki, ibid.). Surprisingly, the homologous gene from S. pombe has been isolated by complementing the same S. cerevisiae tpil mutation. The S. pombe TPI gene, designated as POT1 (for pombe triose phosphate isomerase), has been cloned from a library described by Russell and Hall Biol. Chem. 258: 143-149, 1983) which contains genomic S. pombe DNA that has been partially digested with Sau3A and inserted into the vector YEpl3. A preliminary DNA sequence (by the method of Maxam and Gilbert, Meth. in Enzymology 65: 497-559, 1980) has demonstrated that the POT1 gene codes for the TPI protein and said protein is homologous with TPI proteins from other organisms (see Alber and Kawasaki, ibid.). This POT1 DNA 20 sequence is given in Figure 5, together with the S. cerevisiae TPI1 DNA sequence and the respective protein sequences.

The S. pombe POT1 gene is preferred in this example over the S. cerevisiae TPI1 gene as a selectable marker in S.

cerevisiae. Foreign genes, such as POT1 in S. cerevisiae, may not function well in an alien host cell and therefore may necessitate a higher copy number to complement a host cell defect. Also the selectable POT1 gene on a yeast plasmid allows for the use of the endogenous TPI1 promoter and TPI1 terminator (control regions that show no homology with POT1) for expression of commercially important genes on the same vector. Because POT1 and the flanking regions of TPI1 show no homology, intramolecular recombination and subsequent plasmid instability are reduced. Finally, the POT1 gene is not likely to recombine with the S. cerevisiae chromosomal DNA because it shares little homology at the '~i I (C 1 j i 't 0 00 a0 0 000 0 0 00 Sos oa ?s c* 0 04 0 0 0 04« 1Q1 I n 0 0. 0 4 Sfl t t oc a c fr« *1 t -22- DNA level with the TPII sequence and much of the TPI1 gene has been deleted in the host strains. Thus, POT1 containing plasmids may remain at high copy numbers which are desirable for the elevated expression of foreign genes of commercial interest in yeast.

A plasmid comprising the POT1 gene was identified from the S. pombe library of Russell and Hall (ibid.) by complementation of the tpil mutation in S. cerevisiae strain N587-2D (Kawasaki and Fraenkel, ibid.).

A restriction map of this plasmid, pPOT, is depicted in Figure 6. Because pPOT contains the vector YEpl3, it is inherently unstable, since it lacks replication functions necessary for the maintenance of 2-micron plasmids in yeast. Therefore, the POT1 gene may be moved into more competent vectors, such as Cl/1 and related vectors that contain the entire 2-micron plasmid sequences. Plasmid C1/1 was derived from pJDB248 (Beggs, Nature 275: 104-109, 1978) and pBR322 as described in Example 3 herein. It contains all of the yeast 2-micron plasmid DNA, a select- 20 able LEU2 gene, and pBR322 sequences.

The POT1 gene was isolated from pPOT as a BamHI-XbaI restriction fragment of nearly 3,400 base pairs and was inserted into the corresponding polylinker sites of pUC13.

The resulting plasmid is pUCPOT, a partial restriction map 25 of which is shown in Figure 6.

The pUCPOT plasmid was cut with SalI and religated to delete about 1,800 base pairs of S. pombe and S. cerevisiae DNA. This resulting pUCPOT-Sal plasmid is illustrated in Figure 6.

The POT1 gene was put into C1/1 in the following manner.

As both Cl/1 and pUCPOT-Sal have a BglI site in the ampicillin resistance gene and a unique BamHI site at some other location, the POT1 fragment of pUCPOT-Sal may be f r r~ i ia r aar 1 40 00 0 O 44q 0~ 1 -23substituted for a portion of the pBR322 region of Cl/1.

Cl/1 was cut with BglI and BamHI to liberate a large fragment of nearly 7,700 base pairs that contains part of r the amp gene, all 2-micron DNA, and the LEU2 gene.

Likewise, pUCPOT-Sal was cut with BglI and BamHI to liberate a fragment of nearly 3,400 base pairs that contains the other portion of the amp r gene and the POT1 gene. These two fragments were ligated to form pCPOT, which contains a "restored" selectable amp r gene, the POT1 gene, the LEU2 gene, all 2-micron DNA, and the bacterial origin of replication region from pUC13 (the bacterial origin region from pUC13 allows for a higher copy number of plasmids in E.

coli than does the origin region of pBR322).

E. coli strain HB101 transformed with pCPOT has been deposited with ATCC under accession number 39685.

The POT1 gene may also be inserted into Cl/1-derived vectors by a similar construction. For example, the plasmid pFAT5 (FIG. 7) contains an expression unit for the production of human alpha-1-antitrypsin (AT) inserted into Cl/1. This expression unit, prepared as described in Example 4 consists of the TPIl promoter, the AT cDNA sequence, and the TPIl transcription terminator. A restriction map of pFAT5 is given in Figure 7.

was cat with BglI and BamHI to liberate a fragment (2,200 base pairs) that contains the AT gene and the TPIl terminator. Also liberated is a BglI-BamHI fragment which is identical to the Cl/1 BglI-BamHI fragment described above, except that the fragment from pFAT5 contains an additional 900 base pairs that comprise the TPIl promoter.

This latter pFAT5 piece and the pUCPOT-Sal 3400 bp BglI-BamHI fragment (described above) are ligated to form the plasmid pFPOT, which has the restriction map shown in Figure 7.

:I

B

rr

I*

i v 1 1 i i -24- The vector pFPOT was cut at the unique BamHI site to allow for the insertion of the 2,200 base pair AT gene and TPI1 terminator fragment from pFAT5. The cloning of the 2,200 base pair fragment in the proper orientation into pFPOT allows for the expression of human AT in this yeast vector.

The properly ligated product is designated pFATPOT, whose restriction map is given in Figure 7.

B. Disruption of host TPI gene The Saccharomyces cerevisiae TPI1 gene has been cloned and sequenced (Kawasaki and Fraenkel, ibid. and Alber and Kawasaki, ibid.). The plasmid pTPIC10, comprising the structural gene for the TPI protein, has been described in Alber and Kawasaki (ibid.). A BglII site exists at DNA position 295 in the coding region of TPI1, and another BglII site is located approximately 1,200 base pairs away a in the 5' flanking region. These BglII sites are conven- 0o o ient cloning sites for deleting part of the TPI1 gene and o af for inserting another gene, such as the yeast LEU2 gene.

Such a construct can be used to produce a disruption of the t Xt 20 genomic TPI1 locus in a transformed host.

At approximately -1800 in the 5' flanking region of TPI1 is a Pstl site. In pTPIC10, therefore, the TPI1 gene is flanked by a PstI site on the 5' side and by a SalI site (in the tetr gene) on the 3' side. This PstI-SalI fragment which contains TPI1 was inserted into pUC13 at the PstI and SalI sites to produce pUCTPI. A restriction map of the PstI-SalI insert (into pUC13) is given in Figure 8.

The plasmid pUCTPI was then cut with BglII and the two DNA o' fragments were separated by electrophoresis. The larger 30 fragment was purified and phosphatased to prevent self-ligation. Into the BglII sites of this DNA was ligated the yeast LEU2 gene, which was removed from the plasmid YEpl3 (Broach, et al., Gene 8: 121-133, 1979) as a BglII fragment. The resulting plasmid was pUCTPI-LEU2, which carries i-i Irl( RII~ l-U~il~ It I 1 a partial deletion of TPI1 and an insertion of LEU2.

pUCTPI-LEU2 is depicted in Figure 8.

The plasmid pUCTPI-LEU2 was cut with PstI and BamHI to linearize the DNA. The yeast sequences were then isolated from the pUC13 sequences by electrophoresis and gel purification. The yeast DNA portion depicted in Figure 8 was used to transform S. cerevisiae strain E2-7B (ATCC No.

20689), which is deficient for LEU2, in order to "disrupt" the TPI1 chromosomal gene (Rothstein, ibid.). Leu trans- 10 formants were selected on a synthetic (modified Wickerham's) medium (Mortimer and Hawthorne, in Rose and Harrison, eds., The Yeasts vol. 1, 385-460, Academic Press, 1969) which contained 3% glycerol and lactate (neutralized to pH 1M Sorbitol, and no leucine. The transformants were screened for a TPI deficiency by their i-ability to grow on YEP-Dextrose. One tpi transformant was found among the first 99 transformants screened. This strain was designated as E2-7BAtpi#29 (hereinafter Atpi#29) Atpi#29 grew on YEP-3% Glycerol-l% Lactate but not on YEP-Dextrose.

Enzyme assays (Clifton, et al., Genetics 88: 1-11, 1980) were run on crude cellular extracts and confirmed that Atpi#29 was lacking detectable levels of triose phosphate isomerase activity.

Atpi#29 may be crossed to other yeast strains to form diploids that are heterozygous for the tpi deletion. Such diploids may be sporulated so that other strains deficient for triose phosphate isomerase can be generated. For example, Atpi#29 has been crossed to E8-10A (MATo eu2) (a spore segregant of the cross E2-7BxGK100[ATCC 20669]) to 30 form the diploid, Ell. This diploid has been sporulated to generate the haploid descendant, E11-3C, which has the following genotype: MATa pep4-3 tpil. E11-3C has been crossed back to Atpi#29 to form a diploid, E18, that is homozygous for the tpil deletion. E18 may be preferred over Atpi#29 as a host strain for a plasmid because it has no amino acid requirements, has larger cells, and grows ~aBr 1 4 IAr

I

I P 01 r 0 It 6 II iij -26faster. These tpi strains are deleted for the genetic material which codes for the glycolytic function and are, therefore, expected to be nonreverting stable) mutants, C. Transformation of the POT1 gene into S. cerevisiae tpi deletion strains.

The plasmids pFPOT and pFATPOT were transformed into Atpi#29 and related tpi deletion strains. The yeast mutants were grown aerobically overnight to late log phase in YEP-2% Galactose at 300. Transformation conditions were as described by Beggs (ibid.), except that the cells were allowed to recover at 300 for 1-2 hours in 1M Sorbitol containing YEP-3% Glycerol-l% Lactate or YEP-2% Galactose, instead of YEP-Dextrose, before plating the cells in top agar. The top agar and plates contained synthetic, modi- So°o fied Wickerham's medium with 1M Sorbitol and 2% Dextrose.

o o After thret days at 300, transformants were visible and i 0 were picked out of the agar for replating onto YEPD.

Thereafter, the transformants were maintained on YEPD or 0 0.o 20 other complex media containing dextrose.

S009 Strain E18 transformed with pFATPOT was designated ZYM-3.

It has been deposited with ATCC under accession number 20699.

Stability of pFPOT and pFATPOT on complex media. To study plasmid stability, colonies from a single cell were inoculated into tubes containing YEPD and allowed to grow to a total population of 10 cells (approximately 30 divisions).

The yeast cells were sonicated to break up clumps, diluted to appropriate numbers, and plated onto YEP-2% Galactose or 30 YEP-2% Glycerol-l% Lactate, which allows the growth of tpi cells (with or without the plasmids carrying the POT1 gene). The colonies which arose on YEP-Galactose were then replica plated onto YEPD to screen for the loss of the plasmid tpi cells which have lost the A 1 j l-.ii i ii---1 so 0 0 0* 0 005 00 0 00 0 000 0 0*" -27- POT1-containing plasmid will not grow on dextrose). The results, summarized in Table 2, indicate that the pFPOT and pFATPOT plasmids are stable in the yeast tpi deletirn strains. They are surprisingly much more stable than yeast plasmids containing centromeres. Centromere-bearing plasmids (which are low in copy number) are among the most stable plasmids reported for yeast and are generally lost at a frequency of around 1% of cells per division on complex media (see Murray and Szostak, ibid., for a review of centromere plasmid stability). As Table 2 indicates, the POT1 plasmids described herein are lost at a frequency Sof less than 1% after 30 divisions on complex media in tpi deletion strains.

D. Expression of human alpha-1-antitrypsin in S. cerevisiae using POT1 plasmids To test the use of the POT1 plasmids for enhancing expression of foreign proteins in a transformed yeast, plasmids pFATPOT and pFAT5 were used to transform S. cerevisiae strains Atpi#29 and E2-7B respectively. Transformed cells 20 were selected in leucineless media containing dextrose.

Cultures were grown at 30 c to an O.D.

60 0 of 3-4. Cell extracts were prepared and assayed for AT as described in Example AT produced by pFATPOT/Atpi#29 represented 4-6% of total soluble protein. AT produced by pFAT5/E2-7B represented 2-3% of total soluble protein.

Although plasmid copy numbers are difficult to accurately measure and represent a population average, empirical observations of gene product quantities provide an indication of relative plasmid levels, given that the expression unit (promoter, gene of interest, terminator) remains the same. pFATPOT therefore appears to be functionally greater in number than pFAT5, from which it was derived. Because the two transformed strains are nearly identical c t C

(C

c (c cc C c c Ct I C -28genetically (Atpi#29 being derived from E2-7B by plasmid-directed mutagenesis) and were grown under the same conditions, these results are indicative of the value of the herein- described stable plasmid expression system over previously described vectors.

TABLE 1: STABILITY OF CDC4 PLASMIDS Isolate Total Number Colonies CDC4 Trp Leu+ 1(BELL 1) 123 123 123 123 2 80 80 80 3 83 80 80 83 4 96 96 96 96 88 88 88 88 6 115 115 115 115 aCells were grown in liquid complex medium (YEPD) at 250 for 30 generations, then plated on YEPD at 250.

b

S

b Cells were replica plated to YEPD at 370. Cells lacking an intact CDC4 gene failed to grow at this (restrictive) o temperature.

0009 20 Cells were replica plated to medium lacking tryptophan.

Si d SdCells were replica plated to medium lacking leucine.

t t

IC'

-29- TABLE 2: STABILITY OF POT1 PLASMIDS VS. Total Experiment Plasmid/Strain Colonies a TPI Loss c 1 pTPIC10/Atpi#29 234 163 30.3 2 pFPOT/Atpi#29 308 308 0 3 pFATPOT/Atpi#29 471 471 0 4 pFATPOT/E18(ZYM-3) 1104 1104 0 pFATPOT/E18(ZYM-3) 634 632 0.32 6 pFATPOT/Atpi#29 426 426 0 2-6 pooled data 2943 2941 0.07 aThe plasmid/strain combinations were grown on YEPD plates until easily visible colonies of approximately 10 to 105 cells were seen. These colonies were used to inoculate 6ml of YEPD liquid medium. The cultures were grown aerobically overnight to a cell density of 1-3x10 cells/mi and were oo plated onto YEP-2%Glycerol-1%Lactate or YEP-2%Galactose.

oor Each of these media would allow tpi strains to grow, although the resulting tpi colonies arose more slowly than 20 tpi colonies. Only 100-300 cells were distributed on each Splate so that each colony (whether tpi or tpi would be countable.

b The colonies were replica plated onto synthetic media containing dextrose at a 2% final concentration. Cells i 25 which had lost the triose phosphate isomerase gene on the I plasmids were unable to grow.

cThe Loss" represents the frequency of cells that had lost the plasmid after nearly 30 divisions in YEPD. The pooled data for experiments 2 to 6 indicate that the POT1 plasmids are extremely stable over these many divisions and are lost at a combined frequency well below 1% in 30 cell doublings.

4a.

~lo~ o o0 s 00 0 04 *a 1 0 t 0 4 Example 3 Preparation of Plasmid Cl/1 Cl/1 was constructed from plasmid pJDB248 (Beggs, J., Nature 275, 104-109 (1978)). The pMB9 sequences were removed from pJDB248 by partial digestion with Eco RI and were replaced by pBR322 DNA which was cut with Eco RI. The restriction map of Cl/1 is given in FIG. 6. The Cl/1 plasmid contains the entire 2-micron DNA from yeast (S.

cerevisiae), with a pBR322 insertion at an EcoRI site. It also contains the LEU2 gene.

Example 4 Preparation of Plasmid The gene coding for the predominant form of human alpha-1antitrypsin (AT) was isolated from a human liver cDNA library by conventional procedures using the baboon sequence (Kurachi et al., Proc. Natl. Acad. Sci. USA 78: 6826-6830, 1980; and Chandra et al., Biochem. Biophys. Res.

Comm. 103: 751-758, 1981) as a DNA hybridization probe.

The library was constructed by inserting human liver cDNA 20 into the PstI site of the plasmid pBR322 (Bolivar et al., Gene 2: 95-113, 1977). The AT gene was isolated from the library as a 1500 base pair (bp) PstI fragment. This fragment was inserted into the PstI site of pUC13 to produce the plasmid pUCal. In pUCal, the AT sequence is 25 flanked on the 3' end by XbaI and EcoRI sites in the polylinker.

The TPI terminator was purified from plasmid pFG1 (Alber and Kawasaki, ibid) as a XbaI-EcoRI fragment of approximately 700 bp and inserted into pUCal which had been 30 cleaved with XbaI and EcoRI. This construct was then cut with EcoRI, and oligonucleotide linkers (sequence:

AATTCATGGAG

GTACCTCCTAG) were added, in multiple linked copies, to provide a BamHI site to the 3' end of the TPI terminator.

The resultant plasmid is known as 11A I 0 4 d I: i -~A4 7 -31- 0 a0 0 6 as 0 a o 0 0 *0 a a «o 4. s 000 0000 The TPI promoter fragment was obtained from plasmid (Alber and Kawasaki, ibid). This plasmid was cut at the unique KpnI site, the TPI coding region was removed with Bal31 exonuclease, and an EcoRI linker (sequence: GGAATTCC) was added to the 3' end of the promoter. Digestion with BglII and EcoRI yielded a TPI promoter fragment having BglII and EcoRI sticky ends. This fragment was then joined to plasmid YRp7' (Stinchcomb, et al. Nature 282: 39-43, 1979) which had been cut with BglII and EcoRI. The resulting plasmid, TE32, was cleaved with EcoRI and BamHI to remove a portion of the tetracycline resistance gene. The linearized plasmid was then recircularized by the addition of the above described EcoRI-BamHI linker to produce plasmid TEA32. TEA32 was then cleaved with BglII and BamHI, and the TPI promoter was purified as a fragment of approximately 900 bp.

To construct plasmid pFAT5, plasmid Cl/1 was linearized with BamHI, and was joined to the 900 bp TPI promoter fragment from TEA32. The resulting construct, known as 20 plasmid F, has a unique BamHI site located at the 3' end of the TPI promoter. This plasmid was cut with BamHI and a 2200 bp BamHI fragment, comprising the AT coding sequence and TPI terminator, was purified from BAT5 and inserted into the BamHI site. The resulting plasmid, known as 25 pFAT5, is illustrated in Figure 7.

Example Assay for Alpha-1-Antitrypsin As a control, 10 microliters (1 microgram) of a solution of 100 microgram/ml trypsin, 100 microgram (100 microliters) of bovine serum albumin and 100 microliters of 0.05 molar TRIS, pH 8.0 buffer containing ImM benzoylargininoyl-p-nitroanilide were mixed, and the increase in absorbance at 405 nm was measured over time in a spectrophotometer. The absorbance value of this solution was used as a standard for 100% trypsin activity. All assayed samples contain equal concentrations of substrate and bovine serum albumin.

*4 00 4 0*0 4 4E 4E+ i r i 1 44 1 04 0 4c Cc :Ce

Claims (14)

1. A method for producing alpha-l-antitrypsin in a host cell having a deficiency in a function necessary for normal cell growth on complex media comprising the steps of: transforming said host cell with a DNA molecule comprising a gene which complements said defi- ciency and a sequence coding for said alpha-l-antitrypsin, sc"VA sequerce opv-rao tVcfvscy" p ro o r culturing the transformants from step in a growth medium which need not contain antibiotics or heavy metals, and need not be depleted of specific nutrients.

2. A method for producing alpha-l-antitrypsin in a host cell having a deficiency in a function necessary for normal cell growth on complex media comprising the steps of: transforming said host cell with a DNA molecule comprising a gene which complements said defi- ciency and a sequence coding for said alpha-l-antitrypsin; culturing the cells from step under 20 conditions whereby said gene functions as a selectable marker for transformant cells.

3. A method according to Claim 1 or 2 wherein said gene is a gene required for host cell division, cell wall biosynthesis, membrane biosynthesis, organelle biosynthe- P* e 25 sis, protein synthesis, carbon source utilization, RNA transcription, or DNA replication.

4. A method according to Claim 3 wherein said gene is selected from the group consisting of genes of the yeast zell division cycle and genes of the yeast glycolytic f 30 pathway. A method according to Claim 4 wherein said gene is a yeast CDC4 gene.

A1- T p., _C 1 i -33-

6. A method according to Claim 4 wherein said gene is a Schizosaccharomyces pombe triose phosphate isomerase gene.

7. A method according to Claim 1 or 2 wherein said gene is from a cell species different from said host cell.

8. A DNA construct comprising a gene which comple- ments a deficiency in a host cell, said deficiency being in a function necessary for normal cell growth on complex media, and a DNA sequence coding for alpha-1-antitrypsin, Sen A ZN? seqonce o e \\'n\c3e eo Qr

9. A DNA construct according to Claim 8 wherein said gene is a gene required for host cell division, cell wall biosynthesis, organelle biosynthesis, protein synthesis, carbon source utilization, transcription or replication.

A DNA construct according to Claim 9 wherein said is selected from the group consisting of genes of the t 2 yeast cell division cycle and genes of the yeast glycolytic S pathway.

11. A DNA construct according to Claim 10 wherein said gene is a yeast CDC4 gene.

12. A DNA construct according to Claim 10 where said gene is a Schizosaccharomyces pombe triose phosphate isomerase gene.

13. A transformant strain containing a DNA construct according to any of Claims 8 through 12. 25

14. A product having alpha-1-antitrypsin activity produced according to the process of any of Claims 1, 3, 4, 5 or 6. CO 2 2, 1 t~ i mr~ r -34- A method for producing alpha-1-antitrypsin in a host cell, and a DNA construct for use therein, substan- tially as hereinbefore described with reference to the drawings and/or Examples. Thc ctep fea- -_aad=emu referred to or indicated in the specification- /ai- or claims of this application, individually Or collectively, and. any and all combinations of any two or more of said steps or Ftz z. Ct I I f DATED THIS 22ND DAY OF OCTOBER 1985 ZYMOGENETICS, INC. AND GLENN KAWASAKI BY ITS PATENT ATTORNEY DAVIES COLLISON t {r (C C S I Hinc1I Cla I HindM Hinc 11 COC4 Cla 1 HindlUr HindM 8amHI pJY5I BarnHl YRp7 HindM Hi: ic] HindMr SLI GATE TO HindJs -CUT p BR322 Hinc 11 1 3 Hindlil -y Hincfl NC Hindl BamHI BomHl OpBR322 *4 4 4 44 4 4 44 4444 4 4 .4 4 o *4 44 4 44 4,944 *444 .4 4 4 494 4 4 4 9 4 4 44 4 9 4 .4 44 4 4 4 .4 HindiD Hinc 11 Hincd EomHI PARTIAL CDC I LINKER ADDITION LIGATE TO BornHl -CUT YRp7 Bam~lHind Ml C DC4 BamHI Eco RI d EcoRI pJY70 EcoRt BarnHl Hindm HindIH RE-CIRCULARIZE LARGE FRAGME T Barn HI EcoRi pJY71 BarnHI4 HindM IHind U] Eco RI CDC BarnHI LIGATE TO BanHl, Hindm-CUTBrHIHdU SpBR322 p84 CDC4 TB32 F IG. I Ps? I EcoRIEcoRI BarnHI YRp7 ECMRTIALleo Pst I pBR322 Pst I SPART IAL SEco RI 9 a, 9 a 904 a Oa p 9. t a, 0*9. S at 9 pa S a p9 949* Pst I E. EcoRI ADD 2.u MW5 BorH* PtI( pBR322) Ps t I I~I EcoRl BcrnHI Pst I pBR32 2 a a pa 4 5 9 49 ~4 94£ a C t CC 'EcoR I I BarnHI Eco RI SYhltndfI BamHI ADD CDC4 FROM pB4, -BarnHI Pst I Pst I FIG.-2 BamHI j BamHI HI HindM BarnHI I Barn CloT *q *9 B am Hl *0e 0 0 0 00 *0.00~ 0 0~ I e CDC4 C l Ia SL IGATE TO Bam HI CUT pUCI13 ClH inc I Hina M CDC4 Clal BamHI Bam-I pBI14 PUC13 SClal SLINKER ADDITION SADD LEU2 FROM YEpI3 BgI I LEU2 BgIII ~'CDC4 BaH BI L BomHl PUCI3 FIG-3 E .~COTRANS FORMANTS a b cd e f g h 05 tw -p -p lwd1% 4a ap o o 4 d FIG.-4 2 p.- SEQUENCE COMPARISON OF S. POMBE AND S. CEREVISIAE GENES FOR TRIOSE PHOSPHATE ISOMERASE (POT! AND TPIl) 4, .44 @4 44~4 *0 *4 p 94 4 4 *4 pombe cerevisiae pornbe cerevisiae pombe cerevisise pornbe ce revi sia e -150 -140 -130 -120 -110 -100 GGATCCATGCCAACCGTTGCTATCGACGGGGTAAATTCCCGAAGCTGGTAATTCCCCT AATTTAGGACTTTAGTCAACTTGCAACATTTACTATITTCCCTTCTTACCTAAATATTTI -80 -70 -60 -50 TAACTC IGIGACTGTCGG CTACGTTATATATAATGAG CGGAAGGG CCCAACTC CGC CC TTCTTTTTAATTCTAAATCAATCTTTTCMTTTTTTTCTCATCTICTTCIA -30 -20 -10 -1 1 TCCCCAACTACATTTCAATAGTAGAACTAGGATCAMA ATG GCA CGT MAA TTC AATCTATAACTACAAAAAACACATACATAAACTAAAA ATG GCT AGA ACT TTC MET-ALA ARC LYS PHE (Met) Thr 44 .44 p o *4 4 4.4.4. p 4~ r S. pombe S. cerevisiae S. pombe S. cerevisiae S. pombe S. cerevisiae S. pombe S. cerevisiae S. pombe S. cerevisiae 30 40 TTT GTC GGT GGT MAC TIT MAG ATG MAT CCC TCT TTT GIC GGT CCI MAC ITT MAA TTA MAC GGI TCC PHE VAL CLY GLY ASN PHE LYS MET ASN GLY SER Leu 70 80 90 MAG ACT ATT ATT GAG GGT TIC MAC ACC ACC MAG MAG GMA ATT GTT GMA AGA TTG MAC ACT GCT TCT LEU CLU SER MET Lys Gin Ile TIC GAG TCC MAA CMA ICC 100 GTT MAC CIT ATC CCA CMA 4 4 p LYS THR ILE ILE CLU CLY LEIJ ASN THR THR LYS LEU ASN VAL CLY Clu Val Arg Ala Ser Ile Pro Giu Asn 110 120 .130 140 150 CAT GIC CMA ACT CIC AIG TIC CCI CMA MC ATG TAG CTG ATC ACC CTC GAM CTT CTI ATG TCT CGT CCA CCT ACC TAG TIA GAG TAG TCT I I S. pombe ASP VAL CLU THR VAL ILE PHE PRO CLN ASN MET TYR LEU ILE THR S. cerevisiae Val Clu Val Val Ile Gys Pro Ala Thr Tyr Leu Asp Tyr Ser F IG.- ~z-a. 160 ACC CGC CMA CAA CTC AAC S. pombe S. cerevisiae S. pombe S. cerevisiae GTG TCT TER ARC Val Set 200 CTC TTC CCC TAC VAL PRE Ala Tyr OTT MCG MC CLN VAL LYS Val Lys 210 MAC MAC MC MCG OCT TCT LYS LYS ASN Ala Ser OAT ATT CMA GTC ASP ILE Gin Val 220 CCC TAC OCT TTC ALA TYR Phe gil t #99; a *9 a 9. 9, 9 9 *9 99q~ 9k* pornbe cerevisiae pombe cer evis ia a pombc cerevisiae pombe cerevisiae 180 GOC C ACT C Thr ACT C ACC C THR C 270 TAC A TOO C TYR I± Trp V 190 CCC CAA MC OCT CAA MC ALA OLN ASN 240 MAC ACT OCT MAC TCC OTT ASN SER ALA Val1 250 260 CMA TCT TTC ATT CAT OCT GAC CMA ATC MCG CAT OTT OLN SER LEU ILE ASP ALA Asp Cii Ile Lys Val CT ATT ACC OCT OCT MAC CLY ILE THR Ala Lys 280 TTO ACT OCT ATT TTC OCT LEJ THR CLY Ile Leu 9.) 9 9 a .9 9 9 19 Ala.,; 1 S IA f~ S. pombe S..cerevisiae S. pombe S. cerevisiae 290 GAO COT GMA ACA GLU ARC 300 ACC ATC TCT TAC THR ILE Ser Tyr TTT 0CC TTC OCT PHE ALA 310 MCG GAO CAC GMA LYS GLU His CMA CMA 007- CMA OLU OLN Gly 320 GAO TTC MOA TTC OLU PRE Lys p omb e cerevisi pe pombe cerevisiae pombe ce rev isia e pombe cerevisiae 340 MCG ACC MOG MOG ACC MOC LYS THR LYS 380 ATT OCT GAG ATC CT OMA ILE OLY GLU 370 ACT OTC OTT OOT OTO ATC THR VAL VAL Oly le 410 MAC GAO ACC 001 MAG ACT ASN GLU THR 0CC TOT ALA Leu 420 ATC TTO ILE 390 400 ACT TIC 0CC GAG COT GAO ACT TTC GMA GM. MOG MO THR LEU ALA ASP ARC OLU Olu Oiu Lye Lye Oly Lye Leo F I ~tr C K CCr~ r tttf pombe cerevisiae pombe cerevisiae pombe c erev is ia a pombe cei-evisiae pombe cerevisiae pombe cerevisiae pombe cerevisiae pombe cerevisiae pomb a cerevisiae pomnbe cerevisiae pombe cerevisiae pombe cerevisiae 430 OTT OTT GTT OTT OTT CAA VAL VAL. VAL Clu 440 450 CGT CMA TTC MAC CCC ATC OCT GAC AGA CAA TTO MAC OCT GTC ITO CMA ARC CLN LWU ASN A'LA ILE ALA ASP Val Leu Giu TCC MCG ACT MAC SER LYS Thr Asn 520 OCT MAC COT TTC CLY LYS~ Leu ATC CCC ATC AGA ILE ARC 610 COT CTC CMA TTO CLY LEU Clu 490 OCT TAT GAG OCT TAC CMA ALA TYR CLU 460 MOG CIC CAC CMA OTT MAC LYS VAL. CLN Clu Lys 510 TOO CCC ATT TCC CCC ATT TfP ALA ILE 550 GAC OTT CAC OAT ATT CAC CLU VAL. HIS Asp Ile ACT CC OCT OCT TER CLY Ala Ala 540 GAACGCM OCT CMA OAT OCT OLU OLU ALA Asp (CC C CC CC TOO OCT TTC TO TRP *ALA Phe Leu 580 ACC MAC MCA OCT TCC MCG THR ASN LYS Ala Ser COT OTO AGA ATO ARC VAL. Ile 630 CT COT TCC OCT OCT TCC OLY CLV SER 590 OCT OCA TCT CT CAC MCG CLV ALA SER Asp Lys 640 OTT ACC COT OCT MAC OCT VAL THR CLY Ala Asn 680 CAC COT TTC CAT COT TT ASP CLY PHE 600 OTT OCT VAL Al1a CT ACC CLY Ser 690 TTC TTC LEU MCG GAG TTC CTC MCG ITO CAC OAT AIT OTT ACC TIC MCG CAC MC OCCT OAT OTO LYS OLU PHE LEU LYS PRlE HIS ASP ILE Val Thr Lys Asp Lys Ala Val p.- a. 0 e p p0 9* -9 .4 0 a. p 9, 090* p S. pomfbe S. cerevisiae S. pombe S. cerevisiae S. pombe S. cerevisiae S. pombe S. cerevislae S. pombe S. cerevisiae S. pombe S. cerevisiae 700 OTT GGC GOT OCT OTC GCT GGT OCT 710 720 730 TOT CTC MOC OCT GAM TTC OCT ACT MAC ATT GTT TOT TTG MGC CCA GMA TTT OTT CAT ATC ATC MAC VAL GLY OLY ALA SER LEU LYS PRO GLU PHE PRO THR ASN ILE VAL Val Asp Ile Asn 740 750 +1 +10 +20 MAT OTT CAC AGO OTT TMA AMCGTGCATAGACGTTTTATTTGGCGTAMAGCGA TCT AGA MAC TMA GATTMATATMATTATATAAAAATATTATCTTCTTT ASN VAL HIS SER LEU Ser Arg Asn 06 04 +50 +60 +70 +80 ATGACTTTTTTATTCCTTTAGCTTTTTGTCTTTAMATAGGATTTTTTTATATCCT TCTTTATATCTAGTGTTATCTAAAATAMATTGATGACTACGGAAAGCTTTTTTATATIG +100 +110 +120 +130 AATTTTTI'ACAACAMTATTTCATTTATTTTTATTTGCT TTTCTTTTTCATTCTGAGCCACTTAAMTTTCGTGAMTGT *9 9* .9 p. 0 t *4 FIG.- 21 Hind il EcoR I amH] HindM Sou3A Hin Sau3A BamHI4 XbaI BarTnHl, p POT Xba I YE p1 3 Hindml EcoRI E BamHl POT I Sal r HindII SoaI CUT Bom H 1 (HPO SI 3 AND RE-LIGATE BQ1I C iM EcoRI Hindfl Xba.I E2LTI SaI I Sau3A JLIGATE TO Bom HI4X baI, CUT pUCi3 Hindm :l Sau3A, XbaI Sail 11 I BgI 1 4 Barn HI BgI I ,ampr Sail POT nHI OriB oH EcoRI Hindm~ LIGATIE ,/BmHI+ Bgi I '-BarnHl EcoR I *1 0 100 ~J 0 I Eco Rl. 1 Ji J SI -I I agil FIG. -6 7i p. 0 o 0 0 o .00 *0 0 0 p0 p p 0 o 00 p. p Op pp 0 pop. p 0 P P I P P JR 0 P IS S 0 I P P pp p p p p pp P ~d21 1! I. I' Pst I Sau3A- rr I r (41 I. 4 9 4. 9. 4. 9 44 I 4 44 *4ep 4 4444 rst 14 SalI pUC 13 jPst 1 4 Sail. PsiI Bg I I BgIll1 TPI I SlI Bg III 4. 9 4 9 It 4 1 .4 11 C #4119 YEp 13 'BglIfI IPURIFY LEU2 FRAGMENT BamH1 PURIFY ~~kLARGE Psi I ME' 1 'NT Z LIGATE Pst IREIN PUCi3 FiG.-8 I--